Komori
Governance4579RaQualia Pharma Inc.Pharmaceuticals

Corporate Governance Report 26 March 2026

The report describes the governance structure as a company with an Audit and Supervisory Committee, internal committees such as the Nomination and Compensation Committee, and internal procedures for timely disclosure. No specific changes from the previous report are stated.

Worth reading
64In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee5
Nomination and Compensation CommitteeManagement Strategy CommitteeRisk Management CommitteeCompliance CommitteeSustainability Committee (percentage of outside committee members: 非開示)
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeNomination and Compensation Committee, Management Strategy Committee, Risk Management Committee, Compliance Committee, Sustainability Committee (percentage of outside committee members: Not disclosed)
Items this document does not state (6)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not disclosed

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 26 March 2026 | RaQualia Pharma Inc. (4579) timely disclosure | Komori